UNASSIGNED: e17507 Background: The standard treatment for inoperable stage 3 @entity1149 is concurrent chemo-radiation (CRT). In busy centers such as ours, radiation treatment often cannot be started soon. To prevent treatment delays, we performed a phase II study using induction chemotherapy followed by CRT instead of the standard CRT on day one. We report the long-term outcomes with this regimen. METHODS: Forty-one stage 3 @entity1149 @entity1 (pts), with performance status < 1, were treated between January/2003 and November/2004: 27 males, 14 females, median age 60 (37-70), stage 3A (22 pts) or 3B (19 pts). The induction chemotherapy consisted of two cycles of @entity3003 AUC=5 iv on day 1 and @entity136 1000mg/m2 iv on days 1 and 8 every 3 weeks x2, followed on day 50 by CRT, 60Gy/30 over 6 weeks, concomitantly with @entity1311 50mg/m2 iv and @entity136 100mg/m2 iv on days 1 and 8 every three weeks x 2 cycles. RESULTS: After induction chemotherapy, the partial response was 73.1%, stable disease was 24.4% and one @entity1 progressed. With 72 months of median follow-up, the 3, 4 and 5 year overall survival rates were 34% (14 pts), 22% (9 pts), and 22% (9 pts) respectively. The 5 year progression-free survival was 17% (7 pts). During CRT, grade 3 @entity1398 , @entity882 , and @entity417 occurred in 8, 3, and 3 pts respectively, and grade 4 @entity1398 and @entity882 in one @entity1 each. There were only 2 possible late @entity137 (beyond 1 year) identified, including one case of @entity453 and one case of second @entity5 within the treatment field ( @entity418 ). Twelve pts received further lines of chemotherapy. CONCLUSIONS: In addition to its favourable acute @entity137 profile and response rates, at a median follow-up of 72 months, this regimen demonstrates a better than expected survival outcome with minimal late @entity137 , deserving further investigations.

Can combined chemo-radiation be started after induction chemotherapy in the curative treatment of @entity1149 ( XXXX )? A multicenter, phase II study 5-year update.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity418 :: ('MESH:D004938', 'Disease') :: ['esophageal cancer'] @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']
@entity1149 :: (MESH:D002289,Disease) :: ['NSCLC']
